Researchers Look into Use of Psychedelics in Treating Autism

Various studies have found that psychedelics may provide the potential to treat a range of mental health conditions. Anecdotal evidence from individuals such as Aaron Orsini has also shown that drugs such as MDMA, psilocybin and LSD may be useful in managing autism.

Orsini, who has in the last eight years or so consumed the aforementioned substances to help manage his autism symptoms, recently wrote a book detailing his experiences with psychedelics. Despite this, researchers are hesitant about the use of psychedelics by individuals with autism.

Scientists know that psychedelic drugs primarily act on the serotonin system, which is already compromised in autism. This is based on studies carried out between the late ‘50s and ‘70s, which tested the use of LSD and psilocybin in autistic adolescents and children. However, they don’t know how the biological differences that underlie the condition may intersect with the effects of these drugs.

Currently, pharmaceutical firms and scientists are looking into this in an effort to learn more about the possible risks and benefits of using psychedelics, including psilocybin, LSD and MDMA, in autism treatment.

Mercer University associate professor of pharmaceutical sciences, Clinton Canal, stated that more studies were needed to learn more about this. The only study conducted since the ‘70s that monitored autistic individuals who used a psychedelic substance was carried out by clinical psychologist Alicia Danforth of the Lundquist Institute for Biomedical Innovation.

For their study, Danforth and other researchers recruited autistic adults and administered MDMA to each of them. Each of the participants also underwent psychotherapy sessions, both while they were under the influence of the MDMA as well as when they were sober.

The researchers found that some participants recorded decreases in their social anxiety, noting that the drug didn’t work for everybody but produced profound effects when it did.

Danforth’s research was funded by MAPS, which conducted a study last year that showed positive results in the use of MDMA in treating PTSD.

The increase in studies on psychedelic treatments for neuropsychiatric conditions such as depression, chronic pain and PTSD is being led by different companies and organizations that are looking into the use of a range of psychedelic compounds in the treatment of such conditions.

Some firms, including MindMed, are also looking into the use of a molecule that has similar properties with MDMA in treating social anxiety in individuals with autism. Additionally, other companies are exploring the use of psychedelic drugs in the treatment of conditions, such as depression, that usually co-occur in autistic individuals.

With companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) engaged in developing vaporization technology specifically for psychedelics as others work on the drug formulation aspects, this industry looks set for massive growth in the years to come.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050